Mylan N.V. (MYL) Issues FY17 Earnings Guidance

Mylan N.V. (NASDAQ:MYL) updated its FY17 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $4.45-4.70 for the period, compared to the Thomson Reuters consensus estimate of $4.59. The company issued revenue guidance of $11.75-12.5 billion, compared to the consensus revenue estimate of $12.07 billion.Mylan N.V. also updated its FY18 guidance to $5.40 EPS.

MYL has been the subject of a number of analyst reports. Zacks Investment Research cut Mylan N.V. from a buy rating to a hold rating in a research note on Wednesday, November 8th. Royal Bank Of Canada upped their price objective on Mylan N.V. from $32.00 to $37.00 and gave the stock a sector perform rating in a research note on Tuesday, November 7th. Cantor Fitzgerald set a $34.00 price objective on Mylan N.V. and gave the stock a hold rating in a research note on Tuesday, October 31st. BidaskClub upgraded Mylan N.V. from a hold rating to a buy rating in a research note on Friday, October 27th. Finally, Mizuho reaffirmed a buy rating and set a $37.00 target price on shares of Mylan N.V. in a research report on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $41.49.

Mylan N.V. (NASDAQ MYL) traded up $0.28 during trading on Wednesday, reaching $37.85. The company had a trading volume of 3,732,800 shares, compared to its average volume of 5,986,239. The firm has a market capitalization of $20,300.00, a price-to-earnings ratio of 7.99, a price-to-earnings-growth ratio of 2.06 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87.

Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. Mylan N.V. had a return on equity of 20.63% and a net margin of 7.28%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.38 EPS. sell-side analysts anticipate that Mylan N.V. will post 4.56 earnings per share for the current fiscal year.

WARNING: “Mylan N.V. (MYL) Issues FY17 Earnings Guidance” was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with's FREE daily email newsletter.

Leave a Reply